Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

BACKGROUND: The Oxaliplatin plus 5-Fluorouracil /Leucovorin (FOLFOX4) regimen have been approved by Chinese Food and Drug Administration (CFDA), and covered by health insurance for patients with advanced hepatocellular carcinoma (HCC) in China. However, the efficacy of FOLFOX4 for HCC patients is st...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Zhang, Xinji, Guo, Wei, Feng, Jian, Zhang, Tianyi, Men, Lichuang, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555527/
https://www.ncbi.nlm.nih.gov/pubmed/28610406
http://dx.doi.org/10.22034/APJCP.2017.18.5.1225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555527/
https://www.ncbi.nlm.nih.gov/pubmed/28610406
http://dx.doi.org/10.22034/APJCP.2017.18.5.1225

Ejemplares similares